Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T16162 |
Mutated EGFR-IN-1
Osimertinib analog,AZD9291中间体1 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Mutated EGFR-IN-1 (Osimertinib analog) 是用于突变 EGFR 抑制剂设计的有用中间体,例如 L858R EGFR、Exon19 缺失激活突变体和 T790M 抗性突变体。 | |||
T30268 |
AZD9291-345
AZD-9291345,AZD 9291345,AZD9291345 |
||
AZD9291-345 is a compound which has a molecule weight 345, and structurally related to AZD9291. | |||
T2490 |
Osimertinib
AZD-9291,Mereletinib,奥希替尼 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Osimertinib (AZD-9291) 是一种 EGFR 三代抑制剂,抑制二代 EGFR 抑制剂产生的 T790M 耐药突变,具有不可逆性和口服活性。Osimertinib 具有抗肿瘤活性,用于治疗 EGFR 突变的非小细胞肺癌。 | |||
T3634 |
Osimertinib mesylate
甲磺酸奥希替尼,Mereletinib mesylate,奥希替尼甲磺酸盐,AZD-9291 mesylate |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Osimertinib mesylate (Mereletinib mesylate) 是一种不可逆的突变选择性 EGFR 抑制剂,对EGFRL858R 和EGFRL858R/T790M 的IC50值分别为 12 和 1 nM。 | |||
T10433 |
Osimertinib dimesylate
奥希替尼二甲磺酸盐,Mereletinib (dimesylate),AZD-9291 (dimesylate) |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Osimertinib dimesylate is an irreversible and mutant selective EGFR inhibitor (IC50s: 12 and 1 nM against EGFR L858R and EGFR L858R/T790M). | |||
T13564 |
AZ7550
|
MLK; FAK; EGFR; FLT; Tyrosine Kinases; PYK2; MNK; IGF-1R; ACK; BTK; ALK; Drug Metabolite | Angiogenesis; Cytoskeletal Signaling; JAK/STAT signaling; MAPK; Metabolism; Tyrosine Kinase/Adaptors |
AZ7550 是 AZD9291 的活性代谢物,可抑制 IGF1R 活性,IC50为 1.6 μM。 | |||
T13564L |
AZ7550 hydrochloride
AZ7550 hydrochloride (1421373-99-0 free base) |
EGFR; IGF-1R | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
AZ7550 hydrochloride (AZ7550 hydrochloride ) 是 AZD9291 的活性代谢物,可抑制 IGF1R 活性,IC50为 1.6 μM。 |